G. Martinelli | Authors

421 CHESTNUT ST

Articles

Activity of Rituximab in Extranodal Marginal Zone Lymphomas (MALT Type)

March 01, 2002

This phase II study aimed to evaluate the tolerability and activity of the monoclonal anti-CD20 antibody rituximab (Rituxan) in patients with either untreated or relapsed biopsy-proven extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) type, with measurable or evaluable disease.